Ignite Creation Date:
2025-12-25 @ 1:30 AM
Ignite Modification Date:
2026-03-05 @ 7:55 AM
Study NCT ID:
NCT02761694
Status:
TERMINATED
Last Update Posted:
2023-05-06
First Post:
2016-04-29
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)
Sponsor:
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
4440-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None